• Nearly half of Americans are ‘natively resistant’ to COVID-19 due to prior exposure: Dr. Katz

    Nearly half of Americans are 'natively resistant' to COVID-19 due to prior exposure: Dr. Katz  Preventive Medicine Specialist & True Health Initiative President Dr. David Katz joins Yahoo Finance’s Kristin Myers to break down why Gilead says Remdesivir coronavirus treatment could reduce the risk of death if infected.

    from Yahoo Finance https://ift.tt/3fdoscC

  • 3 “Strong Buy” Dividend Stocks With Yields of at Least 7%

    3 “Strong Buy” Dividend Stocks With Yields of at Least 7%Let’s talk about dividend stocks. These have always been popular with income minded investors, who are attracted to the steady payments and are wiling to sacrifice some share appreciation to mitigate overall risk. That’s both a fair trade and a viable investing strategy.It should have held together during the height of the coronavirus pandemic. That is, dividend stocks should have performed their usual role for investors, helping to insulate portfolios from a larger shock during a period of recessionary pressures. But they did not. Too many companies were hurt too badly, as earnings and cash flow plummeted, and many formerly reliable dividends were reduced or even suspended during the crisis.So, 1H20 has been hard on dividend stocks, and just when investors needed them most. Some due diligence, however, can find the continuing dividend champs, those companies that have made it through the initial economic turndown while retaining their dividend policies. These companies are attracting notice for Wall Street’s analysts, as the go-to choices for dividend investors. Using the TipRanks database, we’ve pulled up some details on three of these stocks.Capital Southwest Corporation (CSWC)We’ll start in the finance industry. Capital Southwest, based in Texas, is a business development company – a BDC – with a focus on high-appreciation opportunities. The company provides specialty lending options and financings for middle market players in a variety of sectors. Some of CSWC’s methods include industry consolidations, management buyouts, and recapitalizations.The company’s strong and heavily diversified portfolio helped to insulate it from the corona-inspired economic shutdown. In fiscal Q4, the company's earnings rose sequentially, coming in at 40 cents per share.Dividend investors are more likely to be pleased by management’s announcement, in early June, that the dividend would be maintained, and that between the regular payment and a special dividend release, it would total 51 cents per share. This is the same as the previous two quarters, and comes after a solid year of slow dividend growth. At the current payment, CSWC’s dividend has an impressive yield of 12.77%Covering the stock for JMP Securities, Christopher York sees a company with room to maneuver. He writes, “Capital Southwest remains one of the most attractive ways to gain exposure to lower-middle-market direct originations. We continue to believe core and supplemental dividends remain sustainable… the company has ample liquidity to fund new investments and support portfolio companies, if needed.”In line with his comments, York reiterates his Buy rating on CSWC. His $17 price target indicates confidence in a one-year upside of 35%. (To watch York’s track record, click here)Overall, Capital Southwest has a Strong Buy rating from the analyst consensus, based on a 3 to 1 split between Buy and Hold reviews. The stock is selling for $12.60, and the $14.25 average price target implies an upside of 13% for the coming year. (See CSWC stock analysis on TipRanks)Heritage Commerce Corporation (HTBK)Next up, Heritage Commerce, is a holding company whose main subsidiary, Heritage Bank of Commerce, serves customers in the San Francisco Bay area as well as Santa Clara and Alameda counties. The company offers general banking and deposit services to the public, and originates a range of consumer and commercial loans.Like most companies with direct contact customer service models, Heritage saw earnings plummet in Q1. The sequential drop was 77%; reported EPS was only 6 cents. The earnings loss came even as revenues beat the forecast. At the top line, the $41.77 million reported for Q1 was up 24% year-over-year.Strong liquidity allows Heritage to weather the corona crisis, survive a steep drop in earnings, and maintain its dividend. The company reported $443.4 million in available cash and liquid assets at the end of the first quarter, along with access to another $477.5 million through borrowing. That’s a hefty war chest for any situation.The company has kept up its dividend payments, without reductions, through the health crisis. The current payment is 13 cents per share quarterly, or 52 cents annualized. At this rate, the dividend offers a yield of 7.65%, far above the 2% average found among S&P listed companies. Better, for investors, Heritage has an 11-year history of prioritizing dividend payments.Andrew Liesch, of Piper Sandler, points out that a significant portion of Heritage’s service portfolio – upwards of 7% of the total – consists of retail and food service commercial customers, who are likely to see surge in banking needs when the epidemic fades on the West Coast. He writes, “[R]etail trade exposure includes gas stations with convenience stores while the food service portfolio is mostly QSRs, both of which have been operating while under shelter-in-place and should experience stronger customer volume as auto traffic and commuting return.”Liesch rates this stock a Buy, citing both forward prospects and current liquidity. His $9 price target suggests an upside of 36% in the coming year. (To watch Liesch’s track record, click here)Heritage gets a Strong Buy from the analyst consensus, and that verdict is unanimous. The stock has 3 recent reviews, and they are all Buys. Shares are priced at $6.80, and the $9.33 average price target – slightly more bullish than Liesch’s – implies a 41% one-year upside. (See HTBK stock analysis on TipRanks)Kimbell Royalty Partners (KRP)Last on today’s list of dividend stock is Kimbell Royalty, a land company operating in oil regions across the US. Kimbell invests in mineral and royalty interests, buying up land it can leas to oil and natural gas producers. The company’s revenue is derived from royalties on hydrocarbon extraction from its properties.Kimbell owns over 38,000 active wells, with 43% of its operations in Texas’ Permian Basin. The company entered 2020 after reporting strong year-over-year gains for both Q4 and CY2019, and had also just completed the acquisition of a competing mineral rights company, Springbok, in a $175 million deal.The drop in oil prices during the bear market cycle, and overall lower demand during the coronavirus economic shutdowns, put serious pressure on Kimbell’s revenue stream. Q1 earnings fell sharply, to a net loss of $1.29 per share, and the stock price has still rebounded from the crash earlier this year. Nevertheless, Kimbell management has chosen to maintain a common stock dividend – although the payment has been cut back to 17 cents per share. This annualizes to 68 cents, and gives a robust yield of 8.2%. The company has stated its commitment to distributing up to 50% of available cash to shareholders.Stephens analyst Gail Nicholson cites the company’s dividend policy in his review of the stock, writing, “We are modeling the company’s distribution as a percent of cash flows flat with 1Q20 (~50%) for the remainder of the year and increases to ~100% during 4Q21 (distribution policy is flexible and likely adjusts based on commodity prices). We anticipate the company utilizes the non distributed cash to further improve its balance sheet.”Nicholson gives weight loss a Buy rating, and supports it by raising his price target from $3 to $11. His new target implies a 32% upside potential for the stock. (To watch Nicholson’s track record, click here)All in all, the analyst consensus rating on Kimbell Royalty is a Strong Buy; the stock has 4 Buy and 1 Hold review behind that rating. The $10.25 average price target suggests a 23% premium form the current share price of $8.28. (See KRP stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/2Cp75XE

  • GenMark Diagnostics (GNMK) Stock Is a Winner, But How Much Higher Can It Go?

    GenMark Diagnostics (GNMK) Stock Is a Winner, But How Much Higher Can It Go?The coronavirus has had a negative impact on most but as luck would have it, some companies have benefited from the viral outbreak. Along with those catering to the stay at home climate, healthcare companies’ valuations have soared during the pandemic. You can add GenMark Diagnostics (GNMK) to the latter camp. The molecular diagnostics company has been no slouch in 2020, and shares are up by 288% so far.The stock was on the rise again yesterday after the company released impressive pre-earnings sales results.Specifically, GenMark expects Q2 revenue to come in at roughly $40 million, reflecting a 118% year-over-year increase and way ahead of the $31 million estimate. This is mainly off the back of the company’s ePlex SARS-CoV-2 test, which made up 48% ($16.9 million) of ePlex sales – compared to just 5% in Q1.The medical device specialist anticipates ePlex revenue to be up 195% year-over-year on overall sales of $35.2 million and the placement of 71 ePlex analyzers (up by 48%).In March, GenMark was granted Emergency Use Authorization (EUA) for its ePlex SARS-CoV-2 Test. Despite the strong demand, management has previously said that due to “manufacturing capacity constraints,” it does not expect revenue in 2020 to top $150 million. Nevertheless, Needham analyst Mike Matson expects GenMark to raise guidance when it reports earnings on August 3.The 5-star analyst said, “We believe that the COVID-19 pandemic continued to drive demand for GNMK's Respiratory Pathogen (RP) panel as a "rule-out" test and its separate COVID-19 test during 2Q20. GNMK launched its respiratory Pathogen Panel 2 (RP2) panel on 6/29/20, which added COVID-19 to the prior panel, so we expect the mix to shift back to its respiratory panel going forward… Given the strong ePlex placements and continued tailwind from COVID-19, we believe that GNMK can sustain strong growth throughout 2020.”Accordingly, Matson keep his Buy rating on GenMark intact, along with a $19 price target. What’s in it for investors? A modest upside of 2% from current levels. (To watch Matson’s track record, click here)Over the last 3 months, three other analysts have published a review of the diagnostics player’s prospects, all imploring investors to Buy. Yet, the average price target of $18 implies nearly 4% downside. (See GenMark stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * Apple Is Developing Its Own Graphics Cards- Report * Carnival (CCL) Is Still a Very Risky Cruise Line Stock * 3 Small-Cap Stocks Under $6 That Could See Over 70% Gains * Google Cloud Forges Multi-Year Deal With Renault

    from Yahoo Finance https://ift.tt/2BR6azE

  • Why Warren Buffett and Stanley Druckenmiller missed the market rally: Trader

    Why Warren Buffett and Stanley Druckenmiller missed the market rally: TraderIn a Yahoo Finance Premium webinar, Brian Shannon, CMT discusses why trading legends missed the bulk of the post-Covid stock market rally and explains how traders can avoid common pitfalls, such as impulsive trading, by having a trading plan and knowing their time frame.

    from Yahoo Finance https://ift.tt/327Um6C

  • What to Do with Sunrun (RUN) Stock Right Now?

    What to Do with Sunrun (RUN) Stock Right Now?North Carolina-based asset management firm Massif Capital, LLC released its second-quarter investor letter this month – a copy of which is available for download here. The fund is currently being co-managed by Will Thomson and Chip Russell. In their recent letter to investors, Massif Capital announced that the core portfolio was up 18.3% in the […]

    from Yahoo Finance https://ift.tt/38Lmi1w

  • Mesoblast expands compassionate use COVID-19 program

    Mesoblast expands compassionate use COVID-19 programMesoblast has developed a cellular therapy that may significantly reduce deaths among the most severely sick COVID-19 patients. CEO Dr. Fred Grossman joins Yahoo Finance’s On the Move to discuss what this development could mean in the fight against the virus.

    from Yahoo Finance https://ift.tt/2Ofx2f0

  • Amazon begins rolling out bigger UPS and FedEx-style delivery trucks

    Amazon begins rolling out bigger UPS and FedEx-style delivery trucksAmazon.com is launching a new fleet of bigger, boxier trucks like those favored by rival package carriers United Parcel Service Inc and FedEx Corp , as it fights to fix widespread pandemic-fueled delivery delays that sent customers into the arms of competitors like Walmart Inc . The world’s largest online retailer ordered more than 2,200 heavy-duty Utilimaster “walk-in” delivery trucks from Shyft Group , a Michigan-based specialty vehicle company, an Amazon spokeswoman told Reuters. The company declined to say how many of the vehicles have been sent to Amazon delivery contractors, or where they would be deployed.

    from Yahoo Finance https://ift.tt/322T0Ki

  • Biden unveils economic plan, calls for end to shareholder capitalism

    Biden unveils economic plan, calls for end to shareholder capitalism2020 presidential candidate Joe Biden unveiled his economic plan, and called for an end to shareholder capitalism. Yahoo Finance’s Jessica Smith joins the On the Move panel to discuss.

    from Yahoo Finance https://ift.tt/2ZVPY85

  • A Note On Broadcom Inc.’s (NASDAQ:AVGO) ROE and Debt To Equity

    A Note On Broadcom Inc.'s (NASDAQ:AVGO) ROE and Debt To EquityMany investors are still learning about the various metrics that can be useful when analysing a stock. This article is…

    from Yahoo Finance https://ift.tt/2Of9RkZ

  • A president Joe Biden would be brutal for the stock market — for this simplest reason

    A president Joe Biden would be brutal for the stock market — for this simplest reasonThis market pro tells Yahoo Finance Joe Biden would not be good for investors. The explanation makes sense.

    from Yahoo Finance https://ift.tt/38K5zeR